Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer

Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer

Androgen deprivation therapy (ADT) is the standard care for prostate cancer (PCa) patients who fail surgery or radiotherapy. While initially effective, the cancer almost always recurs as a more aggressive castration resistant prostate cancer (CRPC). Previous studies have demonstrated that chromatin...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Saraç, H, Morova, T, Pires, E, McCullagh, J, Kaplan, A, Cingöz, A, Bagci-Onder, T, Önder, T, Kawamura, A, Lack, NA
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	Springer Nature 2019

Míreanna comhchosúla

EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities
de réir: Yedier-Bayram, O, et al.
Foilsithe / Cruthaithe: (2022)

Assessing the function of chromatin modifying enzymes in medulloblastoma
de réir: Lokumcu, T, et al.
Foilsithe / Cruthaithe: (2016)

Examining the role of chromatin modifying enzymes in medulloblastoma by utilizing a chemical library
de réir: Lokumcu, T, et al.
Foilsithe / Cruthaithe: (2016)

EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities
de réir: Ozlem Yedier-Bayram, et al.
Foilsithe / Cruthaithe: (2022-08-01)

Identification of selective SWI/SNF dependencies in enzalutamide-resistant prostate cancer
de réir: Gokbayrak, B, et al.
Foilsithe / Cruthaithe: (2025)

New Therapeutics to Treat Castrate-Resistant Prostate Cancer
de réir: Ömer Acar, et al.
Foilsithe / Cruthaithe: (2013-01-01)

Androgen receptor signaling and spatial chromatin organization in castration-resistant prostate cancer
de réir: Tianyi Zhou, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
de réir: Ozyerli-Goknar, E, et al.
Foilsithe / Cruthaithe: (2023)

Androgen Receptor-Mediated Transcription in Prostate Cancer
de réir: Doğancan Özturan, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma
de réir: Filiz Senbabaoglu, et al.
Foilsithe / Cruthaithe: (2020-12-01)

Chromatin-modifying enzymes as modulators of reprogramming
de réir: Onder, Tamer T., et al.
Foilsithe / Cruthaithe: (2014)

Identification of selective SWI/SNF dependencies in enzalutamide-resistant prostate cancer
de réir: Bengul Gokbayrak, et al.
Foilsithe / Cruthaithe: (2025-02-01)

Validation of a questionnaire to identify hearing loss among farm operators
de réir: Marjorie C McCullagh
Foilsithe / Cruthaithe: (2012-01-01)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
de réir: Magdalena Schrank, et al.
Foilsithe / Cruthaithe: (2020-01-01)

Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer
de réir: Jai-Shin Liu, et al.
Foilsithe / Cruthaithe: (2022-05-01)

Human blood and bird egg proteins identified in the red paint covering a 1,000-year-old gold mask from Peru
de réir: McCullagh, J
Foilsithe / Cruthaithe: (2021)

AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer
de réir: Seaho Kim, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
de réir: Ezgi Ozyerli-Goknar, et al.
Foilsithe / Cruthaithe: (2023-11-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
de réir: T. N. Skvortsova, et al.
Foilsithe / Cruthaithe: (2017-01-01)

Recognition of CpG island chromatin by KDM2A requires direct and specific interaction with linker DNA.
de réir: Zhou, J, et al.
Foilsithe / Cruthaithe: (2012)

Recognition of CpG island chromatin by KDM2A requires direct and specific interaction with linker DNA
de réir: Zhou, J, et al.
Foilsithe / Cruthaithe: (2012)

The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer
de réir: Veronika M. Metzler, et al.
Foilsithe / Cruthaithe: (2023-04-01)

Chemotherapy options in castration-resistant prostate cancer
de réir: Benjamin A Teply, et al.
Foilsithe / Cruthaithe: (2016-01-01)

Histone demethylase KDM1A promotes hepatic steatosis and inflammation by increasing chromatin accessibility in NAFLD
de réir: Zifeng Yang, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Mechanism of diol dehydration by a promiscuous radical‐SAM enzyme homologue of the antiviral enzyme viperin (RSAD2)
de réir: Honarmand Ebrahimi, K, et al.
Foilsithe / Cruthaithe: (2020)

Human blood and bird egg proteins identified in red paint covering a 1000-year-old gold mask from Peru
de réir: Pires, E, et al.
Foilsithe / Cruthaithe: (2021)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
de réir: Rodriguez-Vida A, et al.
Foilsithe / Cruthaithe: (2015-06-01)

Castration-resistant prostate cancer: potential targets and therapies
de réir: Parray A, et al.
Foilsithe / Cruthaithe: (2012-08-01)

Up-regulation of prostatic cannabinoid receptor type 2 following capsaicin-induced prostatitis in castrated and non-castrated rats
de réir: Alex Tong-Long Lin, et al.
Foilsithe / Cruthaithe: (2016-06-01)

Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer
de réir: Toros A. Dincman, et al.
Foilsithe / Cruthaithe: (2024-02-01)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
de réir: Lixin Mai, et al.
Foilsithe / Cruthaithe: (2020-12-01)

KDM4B promotes acute myeloid leukemia associated with AML1‐ETO by regulating chromatin accessibility
de réir: Takeshi Ueda, et al.
Foilsithe / Cruthaithe: (2021-12-01)

Identifying dual acting small molecule inhibitors for potential treatment of castration-resistant prostate cancer
de réir: Zhengyang Han, et al.
Foilsithe / Cruthaithe: (2023-12-01)

Integrated high-throughput analysis identifies super enhancers in metastatic castration-resistant prostate cancer
de réir: Jie Zeng, et al.
Foilsithe / Cruthaithe: (2023-05-01)

Castration promotes the browning of the prostate tumor microenvironment
de réir: Alejandro Alvarez-Artime, et al.
Foilsithe / Cruthaithe: (2023-09-01)

Prostate progenitor cells proliferate in response to castration
de réir: Xudong Shi, et al.
Foilsithe / Cruthaithe: (2014-07-01)

Optimal treatment for castration-resistant prostate cancer
de réir: Kouji Izumi, et al.
Foilsithe / Cruthaithe: (2014-06-01)

Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy
de réir: Benjamin A. Gartrell, et al.
Foilsithe / Cruthaithe: (2015-08-01)

The role of the lysine demethylases KDM5 and KDM6 in bone malignancies
de réir: Hookway, E
Foilsithe / Cruthaithe: (2016)

Role of KDM2B epigenetic factor in regulating calcium signaling in prostate cancer cells
de réir: Evangelia Pantazaka, et al.
Foilsithe / Cruthaithe: (2024-07-01)